Network Pharmacology and Experimental Validation Reveal the Effects of Chidamide Combined With Aspirin on Acute Myeloid Leukemia-Myelodysplastic Syndrome Cells Through PI3K/AKT Pathway
Chidamide (CDM), a novel histone deacetylase inhibitor, is currently used for patients with peripheral T-cell lymphoma. Aspirin (ASA), an anti-inflammatory drug, has been shown to exert anticancer activity. Herein, we investigated the effect of CDM combined with ASA on myelodysplastic syndromes-deri...
Main Authors: | Simin Liang, Xiaojia Zhou, Duo Cai, Fernando Rodrigues-Lima, Jianxiang Chi, Li Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2021.685954/full |
Similar Items
-
Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway
by: Hao Wang, et al.
Published: (2020-12-01) -
Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia
by: Xuejie Jiang, et al.
Published: (2021-03-01) -
Chidamide in the treatment of peripheral T-cell lymphoma
by: Chan TS, et al.
Published: (2017-01-01) -
A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
by: Bailin He, et al.
Published: (2020-09-01) -
The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer
by: Zhang W, et al.
Published: (2020-05-01)